Bristol Myers Squibb (CELG-RI) Curent Deferred Tax Liability (2009 - 2012)

Bristol Myers Squibb (CELG-RI) reported Curent Deferred Tax Liability of -$10.0 million for Q4 2012, down 66.67% year-over-year from -$30.0 million in Q1 2012, and down 66.67% quarter-over-quarter from -$6.0 million in Q4 2011.

Bristol Myers Squibb (CELG-RI) Curent Deferred Tax Liability (2009 - 2012) Analysis & Trends

Bristol Myers Squibb (CELG-RI) has 4 years of Curent Deferred Tax Liability data on file, last reported at -$10.0 million in Q4 2012.

  • Curent Deferred Tax Liability for Q4 2012 came in at -$10.0 million, down 66.67% year-over-year; the trailing twelve-month figure through Dec 2012 was -$10.0 million (down 66.67% YoY), and the FY2012 annual result was -$10.0 million, down 66.67% from the prior year.
  • Curent Deferred Tax Liability slipped to -$10.0 million in Q4 2012 per CELG-RI's latest filing, from -$6.0 million in the prior quarter.
  • Over five years, Curent Deferred Tax Liability peaked at $8.0 million in Q4 2009 and troughed at -$10.0 million in Q4 2012.
  • A 4-year average of -$3.2 million and a median of -$5.5 million in 2010 frame the typical range for Curent Deferred Tax Liability.
  • The sharpest annual moves came in 2010 and 2011: Curent Deferred Tax Liability plunged 162.5% in 2010, then dropped 20.0% in 2011.
  • A 4-year view of Curent Deferred Tax Liability shows it stood at $8.0 million in 2009, then sank by 162.5% to -$5.0 million in 2010, then decreased by 20.0% to -$6.0 million in 2011, then sank by 66.67% to -$10.0 million in 2012.
  • Business Quant data shows CELG-RI's Curent Deferred Tax Liability at -$10.0 million in Q4 2012, -$6.0 million in Q4 2011, and -$5.0 million in Q4 2010.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Curent Deferred Tax (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn -
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn -
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn -
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn -
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn -
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn -
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn -
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn -
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn -
10 Bristol Myers Squibb - - 8.07 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2012 -10.00 Mn
Dec 31, 2012 -10.00 Mn
Dec 31, 2011 -6.00 Mn
Dec 31, 2011 -6.00 Mn
Dec 31, 2010 -5.00 Mn
Dec 31, 2010 -5.00 Mn
Dec 31, 2009 8.00 Mn
Dec 31, 2009 8.00 Mn